Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour.
In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just months after the announcement of its blockbuster merger. On February 17, 2026, the company revealed that its Q4 net sales
The No. 1 dentist-recommended brand for sensitive teeth has launched Sensodyne Clinical Repair, its newest option for sensitive teeth, a toothpaste designed to address the root cause of tooth sensitivity. Based on data showing that 85% of people with sensitive teeth want solutions that repair sensitivity by addressing the root cause of their pain, Sensodyne developed Clinical Repair to go beyond temporary relief and actively repair sensitive areas of teeth with continued use.
In a move that signals a seismic shift within the consumer staples landscape, Kimberly-Clark (NYSE:KMB) is on the precipice of finalizing its $48.7 billion acquisition of Kenvue (NYSE:KVUE). This colossal deal, if ratified by shareholders tomorrow, January 29, 2026, would create a diversified powerhouse with a formidable
In a bold move to transcend its identity as a legacy paper commodities giant, Kimberly-Clark (NYSE: KMB) has launched a massive $48.7 billion bid to acquire Kenvue (NYSE: KVUE), the consumer health powerhouse behind iconic brands like Tylenol and Neutrogena. The cash-and-stock deal, which represents one of the largest
As 2025 draws to a close, the consumer staples sector is witnessing one of its most dramatic transformations in decades. The recent announcement that Kimberly-Clark (NYSE:KMB) will acquire Kenvue (NYSE:KVUE) in a deal valued at approximately $48.7 billion has sent shockwaves through the market, but it is
Haleon, a global leader in consumer health, today announced it has been honored in Fast Company’s 2025 Brands That Matter list in the Family of Brands category, which highlights companies that created cultural moments for multiple brands across their portfolios. The annual list recognizes organizations that demonstrate cultural relevance, meaningful consumer connection, and a clear commitment to purpose.
The financial markets have kicked off the week with a significant surge, largely propelled by the blockbuster acquisition of Kenvue Inc. (NYSE: KVUE) by Kimberly-Clark Corporation (NYSE: KMB). This monumental $48.7 billion cash-and-stock deal, announced on November 3, 2025, has sent positive ripples through the stock market, particularly benefiting
Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world’s #1 AI CRM, today announced that Haleon will leverage Salesforce to drive more effective engagement with pharmacies and healthcare professionals worldwide.
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma Walmsley.
Langhorne, PA – September 27, 2025 – Investors in NEXGEL Inc. (NASDAQ: NXGL), a company at the forefront of hydrogel technology, are closely watching the trajectory of its equity warrants (NXGLW). While NEXGEL has demonstrated impressive revenue growth and expanding gross margins, its persistent unprofitability and a recent "going concern" disclosure have
Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence comes after a period of intense pressure, primarily fueled by controversial, unproven claims linking its flagship Tylenol product to neurodevelopmental
Haleon (LSE: HLN), a global leader in consumer health, and Brightseed, the pioneer in AI-driven discovery of bioactive compounds, announced a new collaboration to advance the discovery of plant-based, small molecules with the potential to improve human health. This partnership will leverage Brightseed’s proprietary AI platform, Forager®, as a solution to accelerate scientific insights into the natural world and support Haleon’s mission to deliver innovative, science-led health solutions.
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%.
Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.
Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth.
Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company.
